- Pure Extract Technologies pursues study into psilocybin active treatments
- Study to extend for 250-day period, targeting a number of milestones
- The study is set to be carried out at Toronto Institute of Pharmaceutical Technology, will be supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregor
- Oregon recently voted to legalize psilocybin mushrooms for therapeutic use, a potential legislative movement which may soon be replicated in other jurisdictions
Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, has provided investors with an update in regards to its ongoing study on the formulation and manufacturing of psilocybin-based active treatments through the provision of oral tablets and capsules, as well as a nasal gel which is set to be used as an investigational product (https://ibn.fm/p8GT0).
The study, which is being carried out according to Canadian Good Manufacturing Practice as well as Good Clinical Practice, is set to focus on the formulation, manufacturing and clinical bioavailability testing of rapid onset psilocybin forms – with the latter set to be used in future efficacy clinical trials carried out by both Pure Extracts and…
NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.